Swiss Re Names New Group Chief Digital & Technology Officer; Reorganises Group Operations

Swiss reinsurer Swiss Re Ltd. (SSREY.PK) announced Thursday the appointment of Pravina Ladva as Group Chief Digital & Technology Officer and member of the Group Executive Committee, effective January 1, 2022.

The company noted that Group Chief Operating Officer Anette Bronder will leave the company, and Group Operations will be reorganised.

In the new role, Ladva will lead all technology-related responsibilities. Corporate Real Estate & Services and Communications will report into Group Chief Human Resources Officer Cathy Desquesses, and other functions will report into areas of the organisation that align with their mandates.

Group Chief Executive Officer Christian Mumenthaler said the company is confident that Ladva will continue to advance digitalisation of its entire value chain in her new role.

Ladva is currently Swiss Re's Group Digital Transformation Officer, a role she has held since July 2020. Prior to this, she served as Chief Technology and Operations Officer for Swiss Re's digital white-label provider of property & casualty and life & health insurance, iptiQ.

Prior to joining Swiss Re in 2017, she held various roles at Barclaycard, including COO Digital Marketplace and CIO Barclaycard Business Solutions.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
MTD Products Inc. is recalling 1,774 units of walk-behind self-propelled lawn mowers for potential risk of fire hazard, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the lawn mower can leak fuel when it is stored in the upright (vertical) storage position to pose a fire hazard. Nike Inc. announced its plans to exit the Russian market completely following Russia's ongoing war against Ukraine, reports said. The sportswear major, with more than 100 stores in the country, had suspended operations there in March. Earlier in March, while suspending operations temporarily, the company had said its customers that it couldn't guarantee product shipments. The U.S. Food and Drug Administration unveiled its action plan to advance drug development for rare neurodegenerative diseases, including Amyotrophic Lateral Sclerosis or ALS, in five years. The FDA plans specific actions such as regulatory science initiatives, enhancements to existing programs and new policy initiatives for the purpose. It will use public-private partnerships...
Follow RTT